紫杉醇联合顺铂治疗晚期食道癌的临床效果分析  

Analysis of the clinical effect of Paelitaxel combined with Cisplatin in the treatment of advanced esophageal cancer

作　　者：杨明磊[1] 董彩军[1] 杜学奎[1] 赵国芳[1] 于莲珍[2] 

机构地区：[1]浙江省宁波市第二医院心胸外科,浙江宁波315016 [2]江苏省人民医院消化科,江苏南京210029

出　　处：《中国医药导报》2013年第27期74-75,78,共3页China Medical Herald

基　　金：江苏省财经厅"六大人才高峰"项目(编号2011030)

摘　　要：目的研究紫杉醇联合顺铂治疗晚期食道癌的临床效果。方法选择浙江省宁波市第二医院心胸外科2010年11月～2012年10月收治的84例晚期食道癌患者作为实验对象。按照1:1的人数比例将其分为实验组和对照组,实验组给予紫杉醇与顺铂联合的方法进行治疗,对照组采用5-氟尿嘧啶与顺铂联合的方法进行治疗,实验期结束后,比较两组患者的治疗效果。结果实验期结束后,本研究统计了实验组和对照组患者的病灶大小变化情况及其垂直直径情况,实验组完全缓解8例,占19.0%,部分缓解27例,占64.3%,稳定6例,占13.3%,进展1例,占2.4%,总有效率为97.6%;对照组完全缓解1例,占2.4%,部分缓解10例,占23.8%,稳定18例,占42.9%,进展13例,占30.9%,总有效率为69.1%。两组各项指标比较的χ2值分别为3.161、3.764、2.957、4.037和2.745,P值分别为0.01、0.04、0.03、0.01和0.04。结论紫杉醇联合顺铂治疗晚期食道癌相较于其他方法能够有效提高患者的生存质量,延长生存时间,值得临床推广。Objective To study the clinical efficacy of Paelitaxel combined with Cisplatin in the treatment of advanced esophageal cancer. Methods 84 cases with advanced esophageal cancer patients in Department of Cardiothoracic Surgery of Second Hospital of Ningbo City from November 2010 to October 2012 were taken as the experimental ob- jects. The patients in accordance with the proportion of hl were divided into experimental group and control group, the experimental group was given methods of Paelitaxel combined with Cisplatin for treatment, the control group was given the method of 5-Fluorouracil and Cisplatin for treatment, at the end of the experimental period, the treatment ef- fect of two groups was compared. Results After the experimental period, this study counted the changes about the size of the lesion and its vertical diameter of experimental group and control group, the experimental group had complete remission in 8 patients, accounting for 19.0%, partial remission in 27 cases, accounting for 64.3%, stable in 6 cases, accounting for 13.3%, there was one ease of progress, accounting for 2.4%, the total effective rate was 97.6%; the con- trol group of patients had complete remission in 1 case, accounting for 2.4%, partial remission in 10 cases, accounting for 23.8%, stable in 18 cases, accounting for 42.9%, progress in 13 cases, accounting for 30.9%, total effective rate was 69.1%. The X2 value of the indicators was 3.161, 3.764, 2.957, 4.037 and 2.745, P value was 0.01, 0.04, 0.03, 0.01 and 0.04. Conclusion Paelitaxel combined with Cisplatin in the treatment of advanced esophageal cancer com- pared with other method can effectively improve the quality of life of patients, prolong the survival time, which is wor- thy of the clinical promotion.

关 键 词：紫杉醇 顺铂 晚期食道癌 临床疗效 

分 类 号：R735.7[医药卫生—肿瘤]